Strata Critical Medical, Inc. (SRTA)

Mixed: strong revenue growth and a low-debt balance sheet support the story, but GAAP profitability and trailing free cash flow remain negative. Liquidity is helped by $22.8M cash/investments (as of 2026-06-30) plus an undrawn $30M revolver; valuation is more sensibly viewed through EV/Sales (~2x) and execution on 2026 cash-flow improvement than through earnings-based multiples.

SRTA’s near-term narrative is still digesting the Aug 4 Q2 results and higher FY revenue outlook (regulator-confirmed via recent SEC filings), which recent coverage framed positively. Media sentiment remains mildly positive but is determinately cooler than the May–July acquisition-focused baseline and retail chatter is thin; no regulator-confirmed investigations surfaced (court-case search was CAPTCHA-limited).

Mixed, repairing chart: price (5.40) holds above the SMA200 (5.15), the daily VWAP and the reclaimed EMA9 (5.35), with RSI14 repaired to 47.2 from 35.8, Williams %R improved from -97.6 to -43.4, and the MACD histogram converged from -0.10 to -0.01 (line -0.10 vs signal -0.09, near a bullish cross). Against that, price remains below the SMA20 (5.52), SMA50 (5.50) and EMA21 (5.45), MACD is still negative, ADX14 25.5 reflects a stalled (recently down) trend, and today's volume is below the 20-day average. Chart merits a 3 (mixed, some bullish some neutral), but the trade is Do Nothing: the 20-day average dollar volume of $4,306,517 is below the $5,000,000 liquidity floor, a hard block independent of chart quality.